[go: up one dir, main page]

ES2165109T3 - Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion. - Google Patents

Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.

Info

Publication number
ES2165109T3
ES2165109T3 ES98107383T ES98107383T ES2165109T3 ES 2165109 T3 ES2165109 T3 ES 2165109T3 ES 98107383 T ES98107383 T ES 98107383T ES 98107383 T ES98107383 T ES 98107383T ES 2165109 T3 ES2165109 T3 ES 2165109T3
Authority
ES
Spain
Prior art keywords
tbe
protein
virus
immunization against
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98107383T
Other languages
English (en)
Inventor
Xaver-Franz Prof Dr Heinz
Steven Dr Allison
Christian Doz Dr Mandl
Christian Prof Dr Kunz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0135294A external-priority patent/AT402897B/de
Priority claimed from AT0087195A external-priority patent/AT405607B/de
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2165109T3 publication Critical patent/ES2165109T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION DESCRIBE UNA VACUNA PARA LA INMUNIZACION CONTRA LAS INFECCIONES VIRICAS CON TBE QUE INCLUYE PARTICULAS SUBVIRALES NO INFECCIOSAS, QUE INCLUYEN LA PROTEINA E Y EVENTUALMENTE LA PROTEINA PRM/M, SU VACUNA QUE INCLUYE UN ACIDO NUCLEICO, PARA LA PROTEINA E Y LA PROTEINA PRM/M, QUE DERIVA DEL VIRUS TBE, DONDE LA PROTEINA E ESTA O SE CODIFICA ESENCIALMENTE DE FORMA COMPLETA EN FORMA NATIVA.
ES98107383T 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion. Expired - Lifetime ES2165109T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0135294A AT402897B (de) 1994-07-08 1994-07-08 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT0087195A AT405607B (de) 1995-05-23 1995-05-23 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung

Publications (1)

Publication Number Publication Date
ES2165109T3 true ES2165109T3 (es) 2002-03-01

Family

ID=25594155

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98107383T Expired - Lifetime ES2165109T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.
ES95890132T Expired - Lifetime ES2155510T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95890132T Expired - Lifetime ES2155510T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.

Country Status (9)

Country Link
EP (2) EP0691404B1 (es)
AT (2) ATE206459T1 (es)
CZ (1) CZ282927B6 (es)
DE (2) DE59509667D1 (es)
DK (2) DK0869184T3 (es)
ES (2) ES2165109T3 (es)
FI (2) FI117974B (es)
HU (2) HU219503B (es)
RU (1) RU2150294C1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258788B1 (en) 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CA2481479C (en) 2002-02-26 2012-12-11 Maxygen, Inc. Novel flavivirus antigens
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
HUE027099T2 (hu) 2006-06-06 2016-08-29 Crucell Holland Bv Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284791B1 (de) * 1987-03-20 1995-05-03 IMMUNO Aktiengesellschaft DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser

Also Published As

Publication number Publication date
HU219503B (hu) 2001-04-28
FI117974B (fi) 2007-05-15
ATE206459T1 (de) 2001-10-15
FI118222B (fi) 2007-08-31
CZ282927B6 (cs) 1997-11-12
RU2150294C1 (ru) 2000-06-10
FI20070041A (fi) 2007-01-17
DE59508988D1 (de) 2001-03-01
EP0691404B1 (de) 2001-01-24
FI953371A (fi) 1996-01-09
HU9903233D0 (en) 1999-11-29
EP0869184A3 (de) 1999-05-12
ATE198909T1 (de) 2001-02-15
EP0691404A2 (de) 1996-01-10
HU9501832D0 (en) 1995-08-28
EP0691404A3 (de) 1997-11-12
FI953371A0 (fi) 1995-07-07
EP0869184A2 (de) 1998-10-07
ES2155510T3 (es) 2001-05-16
CZ176995A3 (en) 1996-01-17
EP0869184B1 (de) 2001-10-04
HUT72395A (en) 1996-04-29
HU224199B1 (hu) 2005-06-28
DK0691404T3 (da) 2001-03-19
DE59509667D1 (de) 2001-11-08
DK0869184T3 (da) 2001-12-17

Similar Documents

Publication Publication Date Title
ATE350057T1 (de) Impfstoffzusammesetzung
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
AR023535A1 (es) Nuevas composiciones.
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE542829T1 (de) Impfstoff
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
DE50015170D1 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
NO20023829D0 (no) Proteosom influensavaksine
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
BR0017052B1 (pt) Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método
ES2165109T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
CL2021002727A1 (es) Vacuna con subunidades del vfpc
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
SE9604581D0 (sv) An agent against cancer and virus infections
ES2160235T3 (es) Material de fragancia.
ES2166763T3 (es) Inmunizacion parenteral contra rotavirus.
ES2085163T3 (es) Vacunas contra los parasitos metazoos.
AR027443A1 (es) MUTANTES DE EHV gM-NEGATIVOS
DE60113299D1 (de) Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 869184

Country of ref document: ES